about
MC1R variants predisposing to concomitant primary cutaneous melanoma in a monozygotic twin pair.The determinants of periorbital skin ageing in participants of a melanoma case-control study in the U.K.High-definition optical coherence tomography intrinsic skin ageing assessment in women: a pilot study.Characterization of melanoma susceptibility genes in high-risk patients from Central Italy.In vivo assessment of optical properties of melanocytic skin lesions and differentiation of melanoma from non-malignant lesions by high-definition optical coherence tomographyIn vivo assessment of optical properties of basal cell carcinoma and differentiation of BCC subtypes by high-definition optical coherence tomographyOverview on non-melanoma skin cancers in solid organ transplant recipients.Overlapping DRESS and Stevens-Johnson Syndrome: Case Report and Review of the Literature.The Italian Euromelanoma Day: evaluation of results and implications for future prevention campaigns.Knowledge, perceptions and behaviours about skin cancer and sun protection among secondary school students from Central Italy.Validation of a diagnostic algorithm for the discrimination of actinic keratosis from normal skin and squamous cell carcinoma by means of high-definition optical coherence tomography.The first skin cancer screening day at the Italian parliament: a Euromelanoma initiative.Three-dimensional high-definition optical coherence tomography image acquisition procedure for basal cell carcinoma.Dermoscopic variability of basal cell carcinoma according to clinical type and anatomic location.High-definition optical coherence tomography algorithm for discrimination of basal cell carcinoma from clinical BCC imitators and differentiation between common subtypes.A new algorithm for the discrimination of actinic keratosis from normal skin and squamous cell carcinoma based on in vivo analysis of optical properties by high-definition optical coherence tomography.Establishment of a European Registry for hidradenitis suppurativa/acne inversa by using an open source software.High-definition optical coherence tomography algorithm for the discrimination of actinic keratosis from normal skin and from squamous cell carcinoma.Dermoscopic features of cutaneous melanoma are associated with clinical characteristics of patients and tumours and with MC1R genotype.Selective sunscreen application on nevi: frequency and determinants of a wrong sun-protective behaviour.[Melanoma secondary prevention].[High-definition optical coherence tomography: Presentation of the technique and applications in dermatology].[Contribution of reflectance confocal microscopy in the diagnosis of Kaposi's disease].[Contribution of reflectance confocal microscopy in the diagnosis of extra-mammary Paget's disease].Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.Relationship between sunbed use and melanoma risk in a large case-control study in the United Kingdom[New therapeutic approaches for hidradenitis suppurativa]A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapyDermoscopic features and follow-up changes of acral melanocytic naevi in childhood and adolescenceFrequency of melanocytic nevi in psoriatic patients is related to treatment and not to disease severityEfficacy and tolerability of 5-aminolevulinic acid 0.5% liposomal spray and intense pulsed light in wrinkle reduction of photodamaged skinLymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studiesSex and Gender Aspects for Patient Stratification in Allergy Prevention and TreatmentSunbeds and melanoma risk: time to close the debateAssociation of sunbed use with skin cancer risk factors in Europe: an investigation within the Euromelanoma skin cancer prevention campaignWho, why, where: an overview of determinants of sunbed use in EuropeOverview on vitamin D and sunbed usePrevalence and determinants of sunbed use in thirty European countries: data from the Euromelanoma skin cancer prevention campaign
P50
Q34414747-0F1C0C47-3D07-40B0-ACEA-626694259740Q35448914-45941CC3-BC8A-4021-B921-F58335225C5EQ36065411-26280E8F-D6D6-4F98-A8E0-395EC6867EEBQ36266148-62AD28EE-DF50-465C-84E8-69713ADD322FQ36464231-1188618E-B684-4DEC-ABD8-08D28BAB6440Q37032346-655DB1FA-E355-46AF-86F2-C46B6779E2C6Q38234583-8F683564-5846-4D3E-9198-289AFFCE03C1Q39370823-3BC0208D-A44A-4F42-B7F9-F128D3218458Q39505252-B197BBF0-4242-423A-90D7-491BD5DCB65BQ39649528-35CC9215-7942-4B2B-A7A3-4582165FE400Q39837803-2091207D-4C26-47C2-B5BE-410AF89AF6A7Q42463081-5AF7700C-1178-4D8F-8DC8-6A7BF878FE09Q42467039-286F1286-7D55-4F72-AE1F-7D1F7461C863Q42472062-579364A4-C426-4BFB-A346-134E5C12E633Q42473344-B79835BF-2FAC-461E-856E-9E80FC1E54E5Q42494786-ABA5ACD9-2ABB-4DC1-AEA0-B54EF1B20518Q44302401-B7C1C250-EA77-4E72-AD9E-1BF0C2F4B33AQ48228027-174FFFB9-0F60-4741-B346-33353194AD67Q50224889-211762C2-94A8-4AA9-9EBF-AF358F4E83F4Q51272407-60BE3554-B46F-43C4-9233-A98654F7A865Q52988082-25C8DF9B-46E5-4A1E-94B3-69C0DC025D73Q53521811-3E2709B8-2A2C-4933-B537-6E740F0AF792Q53622593-5B2F11C5-F4F0-47CA-8E29-AD119C4C94C2Q53640817-71E4480A-2705-476C-B761-EF0C616E9E36Q54293195-BE15FA8D-B3AD-431E-AD37-E1B1C2859A70Q56435867-072C27FF-6436-48C9-801B-6D19D2342E37Q57498482-FB410E93-B36F-4090-B26D-DD6427E71AE3Q59085438-56DA1587-F9B5-4D2E-B28B-11C1EB153CF5Q61917331-C9E5FEA7-22AB-4D53-8ED0-EA917C70CA46Q61917338-0A41E876-D015-4D45-BB73-448B157954C7Q61917373-DBC25281-FD7C-485B-97F4-BDB13AD00C89Q87759766-3FB8C04C-419E-4862-BD30-E6D9BDA304A4Q89896183-D8C94E5A-DC45-4E65-93A4-2A2AA0573024Q91194492-9C2D83EB-2475-42D1-A63B-D96E4BC9999BQ91966163-FF10E19D-86DC-4BD3-BB1D-39E6C351A142Q91966177-0797D408-099C-4BFE-8264-BB73A5D8A68BQ91966215-0A6EE801-54FD-4923-B96C-933F1FE047A1Q91966238-89A13329-C57F-4006-A33A-196DA611322A
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-9266-0342
@en
name
M Suppa
@ast
M Suppa
@en
M Suppa
@nl
type
label
M Suppa
@ast
M Suppa
@en
M Suppa
@nl
prefLabel
M Suppa
@ast
M Suppa
@en
M Suppa
@nl
P106
P31
P496
0000-0002-9266-0342